{"id":15922,"date":"2025-09-19T20:29:12","date_gmt":"2025-09-19T17:29:12","guid":{"rendered":"https:\/\/testsunucusu.com\/acibadem\/doctor\/abdullah-buyukcelik\/"},"modified":"2025-12-11T18:19:31","modified_gmt":"2025-12-11T15:19:31","slug":"abdullah-buyukcelik","status":"publish","type":"idel_doctor","link":"https:\/\/acibademinternational.com\/doctor\/abdullah-buyukcelik\/","title":{"rendered":"Abdullah B\u00fcy\u00fck\u00e7elik"},"content":{"rendered":"

<\/p>\n

\n

Prof. Abdullah B\u00fcy\u00fck\u00e7elik<\/strong> is a medical oncologist with a strong clinical and academic background. He earned his medical degree and completed his associate professorship at Ankara University Faculty of Medicine in 2006. Since 2009 he has been affiliated with Acibadem Health Group, where he combines patient care with ongoing clinical practice and collaboration. He is an active member of several professional organizations, including the Febrile Neutropenia Association, Medical Oncology Group, Internal Medicine Association, Medical Oncology Society, and Ankara Medical Oncology Association. His memberships reflect a commitment to multidisciplinary care, oncology research, and improving outcomes for patients with cancer and related complications.<\/p>\n

<\/div>\n

Education<\/strong><\/p>\n

    \n
  • 2006<\/span> Ankara University Faculty of Medicine \/ Associate Professor<\/span><\/li>\n
  • 2001<\/span> Ankara University Faculty of Medicine Medical Oncology<\/span><\/li>\n
  • 1996<\/span> Ankara University Faculty of Medicine Internal Medicine<\/span><\/li>\n
  • 1984 \u2013 1990<\/span> Istanbul University Istanbul Faculty of Medicine<\/span><\/li>\n<\/ul>\n

    Experience<\/strong><\/p>\n

      \n
    • 2009<\/span> Acibadem Health Group<\/span><\/li>\n
    • 2007 \u2013 2009<\/span> Ankara University Faculty of Medicine Department of Medical Oncology \/ Bone Marrow Transplantation Unit<\/span><\/li>\n
    • 2001 \u2013 2009<\/span> Department of Medical Oncology, Ankara University Faculty of Medicine<\/span><\/li>\n
    • 1999 \u2013 2001<\/span> Ankara University Faculty of Medicine, Medical Oncology Residency<\/span><\/li>\n
    • 1996 \u2013 1999<\/span> Ankara Sevgi Hospital \/ Internal Medicine Specialist<\/span><\/li>\n<\/ul>\n

      Memberships<\/strong><\/p>\n

        \n
      • Febrile Neutropenia Association<\/span><\/li>\n
      • Medical Oncology Group<\/span><\/li>\n
      • Internal Medicine Association<\/span><\/li>\n
      • Medical Oncology Society<\/span><\/li>\n
      • Ankara Medical Oncology Association<\/span><\/li>\n<\/ul>\n

        Publications<\/strong><\/p>\n

          \n
        • No abstract available. Angiotensin-converting enzyme inhibitors: do they contribute to delayed chemotherapy induced nausea and vomiting?<\/strong>
          \nMed Hypotheses, 73, 628-629, (2009) Dogan M, Yalcin B, Ozal FG, Buyukcelik A, Utkan G, Icli F, Dogan L.<\/li>\n
        • Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP.<\/strong>
          \nMed Oncol, 2009 Sep 29 Dincol D, Buyukcelik A, Dogan M, Akbulut H, Samur M, Demirkazik A, Senler FC, Onur H, Icli F.<\/li>\n
        • Prognostic significance of serum matrix metalloproteinase 9 (MMP-9) levels in patients with sarcomas.<\/strong>
          \nYaman E, Yalcin B, Utkan G, Akbulut H, Isikdogan A, Sencan O, Buyukcelik A, Demirkazik A, Icli F. UHOD, 18, 79-84, (2008)<\/li>\n
        • The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma.<\/strong>
          \n\u015eencan O, Buyukcelik A, Yalcin B, Boruban M.C, Akbulut H, Demirkazik A, Senler F.C, Onur H, Icli F. Eur J Cancer Care, 17,26-32, (2008)<\/li>\n
        • Lung cancer metastasis mimicking gluteal abscess.<\/strong>
          \nSouth Med. J, 100, 334-335, (2007) Tek I, Iyidir OT, Utkan G, Ceyhan K, Buyukcelik A, Yalcin B, Demirkazik A.<\/li>\n
        • Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer.<\/strong>
          \nIcli F, Akbulut H, Utkan G, Yalcin B, Dincol D, Isikdogan A, Demirkazik A, Onur H, Cay F, Buyukcelik A. J. Surg. Oncol, 95, 507-512, (2007)<\/li>\n
        • Extranodal Hodgkin disease presenting with gluteal mass and hypercalcemia.<\/strong>
          \nSouth. Med. J. 99, 1149-1150, (2006) Utkan G, Buyukcelik A, Yalcin B, Tek I, Doruk H, Dincol D, Erekul S, Baykara M.<\/li>\n
        • Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin.<\/strong>
          \nBuyukcelik A, Onur H, Akbulut H, Bulent Y, Ensari A, Utkan G, Onal BS, Icli F. Tumori, 91, 302-308, (2005)<\/li>\n<\/ul>\n<\/div>\n","protected":false},"featured_media":15923,"template":"","categories":[4,26,842],"class_list":["post-15922","idel_doctor","type-idel_doctor","status-publish","has-post-thumbnail","hentry","category-doctors","category-kayseri-hospital","category-oncology"],"_links":{"self":[{"href":"https:\/\/acibademinternational.com\/wp-json\/wp\/v2\/idel_doctor\/15922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/acibademinternational.com\/wp-json\/wp\/v2\/idel_doctor"}],"about":[{"href":"https:\/\/acibademinternational.com\/wp-json\/wp\/v2\/types\/idel_doctor"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/acibademinternational.com\/wp-json\/wp\/v2\/media\/15923"}],"wp:attachment":[{"href":"https:\/\/acibademinternational.com\/wp-json\/wp\/v2\/media?parent=15922"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/acibademinternational.com\/wp-json\/wp\/v2\/categories?post=15922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}